ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) COO Brendan Teehan sold 5,140 shares of the company's stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $17.90, for a total value of $92,006.00. Following the transaction, the chief operating officer now directly owns 36,340 shares in the company, valued at $650,486. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Brendan Teehan also recently made the following trade(s):
- On Monday, February 26th, Brendan Teehan sold 624 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $24.67, for a total value of $15,394.08.
- On Monday, January 8th, Brendan Teehan sold 731 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total value of $21,900.76.
ACADIA Pharmaceuticals Stock Performance
Shares of ACAD opened at $18.20 on Thursday. The firm's 50-day simple moving average is $23.85 and its two-hundred day simple moving average is $24.48. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $17.56 and a fifty-two week high of $33.99.
They say it’s ‘unstoppable’ – How I made 43,509%
From Investing Daily | Ad
Not long ago I joined Phil Ash for a private one-on-one interview.
And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015…
Without a single loss.
Click here now for the full story.
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The company had revenue of $231.04 million during the quarter, compared to analysts' expectations of $223.79 million. During the same period in the prior year, the company posted ($0.26) earnings per share. The company's revenue was up 69.3% on a year-over-year basis. As a group, equities analysts expect that ACADIA Pharmaceuticals Inc. will post 0.64 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have recently commented on the stock. Morgan Stanley lowered their target price on shares of ACADIA Pharmaceuticals from $40.00 to $30.00 and set an "overweight" rating for the company in a report on Wednesday, March 13th. Stifel Nicolaus boosted their price objective on ACADIA Pharmaceuticals from $25.00 to $27.00 and gave the stock a "hold" rating in a research report on Monday, December 18th. Robert W. Baird initiated coverage on ACADIA Pharmaceuticals in a research note on Tuesday, January 30th. They set an "outperform" rating and a $40.00 target price on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $42.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 7th. Finally, Needham & Company LLC decreased their price target on shares of ACADIA Pharmaceuticals from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Tuesday, March 12th. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $36.12.
View Our Latest Research Report on ACADIA Pharmaceuticals
Institutional Investors Weigh In On ACADIA Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in ACADIA Pharmaceuticals by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,925,641 shares of the biopharmaceutical company's stock valued at $211,463,000 after acquiring an additional 525,048 shares in the last quarter. RTW Investments LP raised its position in ACADIA Pharmaceuticals by 18.3% in the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company's stock worth $241,255,000 after buying an additional 1,793,288 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of ACADIA Pharmaceuticals by 1.7% during the 2nd quarter. BlackRock Inc. now owns 10,039,501 shares of the biopharmaceutical company's stock valued at $240,446,000 after acquiring an additional 170,370 shares during the last quarter. State Street Corp raised its holdings in shares of ACADIA Pharmaceuticals by 2.8% during the third quarter. State Street Corp now owns 6,778,871 shares of the biopharmaceutical company's stock valued at $110,902,000 after purchasing an additional 184,921 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in ACADIA Pharmaceuticals by 6.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,550,906 shares of the biopharmaceutical company's stock worth $85,649,000 after purchasing an additional 271,652 shares during the period. Hedge funds and other institutional investors own 96.71% of the company's stock.
About ACADIA Pharmaceuticals
(
Get Free Report)
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
